## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.25 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($457.48)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. HCA Healthcare Stock: Quiet Rally, Firm Guidance, And A Market Still Deciding What Comes Next**
- Source: AD HOC NEWS | 20260105T015225 | Bullish | Relevance: 100%
- HCA Healthcare's stock has shown a quiet but steady rally, driven by strong fundamentals, consistent guidance, and a focus on returning cash to shareholders. Despite market attention on tech giants, HCA has posted solid gains by offering predictable cash flow and demonstrating resilience against industry headwinds. Wall Street analysts largely maintain a constructive view, seeing continued upside for the defensive leader.

**2. Gateway Investment Advisers LLC Lowers Stake in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20260104T122818 | Bullish | Relevance: 100%
- Gateway Investment Advisers LLC decreased its stake in HCA Healthcare by 6.4% in the third quarter of 2025 by selling 5,610 shares, leaving it with 81,974 shares valued at $34.94 million. This reduction comes as HCA Healthcare reported strong Q3 earnings, beating estimates, and analysts have raised price targets, giving the stock a "Moderate Buy" consensus. An EVP also significantly reduced his holdings, while other institutional investors have bought shares.

**3. Generali Asset Management SPA SGR Has $4.80 Million Stake in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20260103T113403 | Somewhat-Bullish | Relevance: 100%
- Generali Asset Management SPA SGR significantly reduced its stake in HCA Healthcare by 33.4% in Q3, selling 5,643 shares and ending with 11,269 shares valued at $4.803 million. Other institutional investors also adjusted their positions in HCA Healthcare, which has 62.73% institutional ownership. HCA Healthcare exceeded Q3 earnings estimates and has a "Moderate Buy" consensus rating with a $479 price target from analysts.

**4. Is HCA Healthcare Stock the Next Sleeper Mega-Win or a Disaster Waiting to Happen?**
- Source: AD HOC NEWS | 20260103T052601 | Bullish | Relevance: 100%
- HCA Healthcare (HCA) is presented as a quietly performing stock, contrary to trending meme stocks, due to its strong financial performance, significant market cap, and consistent dividend payouts. The article examines HCA's business model, highlighting its scale, the essential nature of healthcare services, and the risks involved like labor costs and regulatory scrutiny. It concludes that HCA Healthcare, while not a viral sensation, offers long-term stability and growth potential for serious investors.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $520 | $505 | +3% |
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Outperform |
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.25 suggests fair value with growth premium. Forward P/E 16.1x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.8B |
| Beta | 1.37 |
| 52W Range | $295.00 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.25 |
| Forward P/E | 16.1 |
| Current P/E | 17.3 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -1.6% to 0.3% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.7pp (needs >4.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.71), momentum weakening. RSI neutral at 52. OFD pattern: +F0N (Breakout).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.34% (CS: 45) | Neutral |
| RSI_14 | 51.7 | Neutral |
| MACD Histogram | -0.71 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.187x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $477.76
- **Stop Loss:** $457.48 (4.2% risk)
- **Target:** $518.32 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 42
- **Position Value:** $20,065.92
- **Portfolio %:** 20.07%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*